A retrospective analysis of two randomized clinical trials of crizotinib in treatment naïve ALK-NSCLC showed that 20% of the patients who had extracranial disease progression, developed new brain metastases (30). The gene discussed is ALK; the disease is non-small cell lung carcinoma.